Drug Interaction Report

Consumer information for this interaction is not currently available.

ADDITIONAL CONTRACEPTION RECOMMENDED: Concomitant use with lorlatinib may decrease the plasma concentrations and efficacy of contraceptive hormones. In vitro studies show that lorlatinib is an inducer of CYP450 3A, the isoenzyme primarily responsible for the metabolic clearance of sex hormones. The use of hormonal contraceptives during treatment with lorlatinib can result in contraception failure. Lorlatinib can also cause embryo-fetal harm when administered to a pregnant woman.

MANAGEMENT: Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with lorlatinib. Since the use of lorlatinib is likely associated with embryo-fetal harm, it is particularly important that patients not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with lorlatinib. Women of childbearing potential should use a highly effective, non-hormonal method of contraception during treatment with lorlatinib and for 6 months after the last dose. Male patients with female partners of reproductive potential should use effective contraception during treatment with lorlatinib and for 3 months after the last dose.

Lorlatinib may reduce the blood levels and effects of norgestimate. If you are using hormonal contraceptives, you may have an increased risk of contraception failure and unintended pregnancy. Lorlatinib is likely associated with major birth defects, so it is particularly important that you do not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with lorlatinib. You should discuss the use of alternative or additional non hormonal methods of birth control with your healthcare provider. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Do not consume grapefruit or grapefruit juice during treatment with lorlatinib. Grapefruit juice can significantly increase the blood levels and effects of lorlatinib, which may result in a greater risk of side effects. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Grapefruit juice may increase the blood levels of certain medications such as norgestimate. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with norgestimate. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.

Information for this minor interaction is available on the professional version.